Abstract
Pharmacogenomics is a medical science that promotes personalized medicine, i.e., providing the right drug at the right concentration at the right time. An individual’s genetic makeup is a determinant as to how pharmacologic medications are absorbed, transported, metabolized, and excreted. Currently, genetic polymorphisms in the genes that produce drug-metabolizing enzymes cause the greatest variance in drug response. Therefore to date, most of the focus for pharmacogenomic testing has been for these genes. There are no pharmacogenomic tests for variances in transport proteins that are in routine clinical practice.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Wu AHB, Babic N, Yeo JT. Implementation of pharmacogenomics into the clinical practice of therapeutics: issues for the clinician and the laboratorian. Personal Med. 2009;6:315–27.
Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized control study. Clin Pharmacol Ther. 2008;83:460–70.
Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007;116:2563–70.
Eckman MH, Rosand J, Greenberg SM, et al. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med. 2009;150:73–83.
Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101:113–21.
Lim HS, Lee HJ, Lee KS, et al. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol. 2007;25:3837–45.
Borges S, Desta Z, Li L, Skaar TC, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther. 2006;80:61–74.
Madlensky L, Natarajan L, Tchu S, et al. Tamoxifen metabolite concentrations, CYP2D6 genotype and breast cancer outcomes. Clin Pharmacol Ther. 2011;89:718–25.
Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 polymorphism and response to clopidogrel. N Engl J Med. 2009;360:354–62.
Shuldinger AR, O’Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849–58.
Pare G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363:1704–14.
Shulding D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010;121:512–8.
Lau WC, Gurbel PA. Antiplatelet drug resistance and drug-drug interactions: role of cytochrome P450 3A4. Pharm Res. 2006;23:2691–708.
Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaenous coronary intervention. The GRAVITAS Randomized Trial. JAMA. 2011;305:1097–105. http://cardiobrief.org/2010/11/16/gravitas-no-benefit-for-clopidogrel-dosing-based-on-platelet-function-test/
Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993;34:1081–5.
Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 Screening for Hypersensitivity to Abacavir. N Engl J Med. 2008;358:568–79.
Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYD2D6 metabolism. N Engl J Med. 2004;351:2827–31.
Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci. 1999;20:342–9.
Cote JF, Kirzin S, Kramar A, et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res. 2007;13:3269–75.
Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustain virologic response in genotype 1 hepatitis C Virus. Gastroenterol. 2010;139:120–9.
Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C. Nature. 2009;461:798–802.
Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–9.
Reisler RB, Murphy RL, Redfield RR, et al. Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS Clinical Trials Group Studies: lessons learned. AIDS. 2005;39:159–66.
Rzany B, Correia O, Kelly JP, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Lancet. 1999;353:2190–4.
McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827–38.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Wu, A.H.B. (2012). Pharmacogenomics: Tailoring Treatment Based on Genotype. In: Best, D., Swensen, J. (eds) Molecular Genetics and Personalized Medicine. Molecular and Translational Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-61779-530-5_3
Download citation
DOI: https://doi.org/10.1007/978-1-61779-530-5_3
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-61779-529-9
Online ISBN: 978-1-61779-530-5
eBook Packages: MedicineMedicine (R0)